Transaction · 0002050167-26-000023

Dandekar Atul

Dandekar Atul, CSBO, reported an open-market or private sale at Maze Therapeutics, Inc. involving 7500.000000 shares for an estimated $206823.75. Reported holdings after the transaction were 26250.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SCSBO
MAZEMaze Therapeutics, Inc.
Filing timeAug 31
Trade dateAug 28, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$26.57
Pre-filing
1mo ago +2.6%1w ago +10.8%1d ago +7.6%
Returns since
7d +0.0%30d +0.0%90d +0.0%180d +0.0%1y +0.0%

MAZE price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
MAZE since 2026-08-31Filed 4 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0002050167-26-000023
Common Stock
Transaction date
Aug 28, 2026
Filed Aug 31, 2026, 10:32 PM · 3d delay
Shares
7.50k sh
$2.75k per share
Estimated value
-$20.6M
Computed from shares × price
Holdings after
26.2k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Direct Ownership Large Holdings Reduction 10b5-1 Detected
-4score
Filing-only score

-4

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

CSBO

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.

  2. F2

    The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.31 to $28.01 per share, inclusive. The reporting person undertake…

  3. F3

    The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025.

Original filing · 0002050167-26-000023
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

MAZE